Welcome to LookChem.com Sign In|Join Free

CAS

  • or

64202-83-1

Post Buying Request

64202-83-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

64202-83-1 Usage

Description

(2E)-22-bromo-14-hydroxy-9,15-dimethoxy-5,11,13,17-tetramethyl-4,26-dioxo-4,9,10,13,14,15,16,17,18,25-decahydro-2,19-methanoazacyclohenicosino[5,4-b][1,4]benzoxazin-10-yl carbamate is a complex organic chemical compound characterized by a unique molecular structure. It features a carbamate group, hydroxy and methoxy functional groups, and a bromine atom, which contribute to its potential pharmaceutical or biological properties. (2E)-22-bromo-14-hydroxy-9,15-dimethoxy-5,11,13,17-tetramethyl-4,26-dioxo-4,9,10,13,14,15,16,17,18,25-decahydro-2,19-methanoazacyclohenicosino[5,4-b][1,4]benzoxazin-10-yl carbamate's intricate arrangement of carbon and hydrogen atoms further suggests its possible use in medicinal applications.

Uses

Used in Pharmaceutical Industry:
(2E)-22-bromo-14-hydroxy-9,15-dimethoxy-5,11,13,17-tetramethyl-4,26-dioxo-4,9,10,13,14,15,16,17,18,25-decahydro-2,19-methanoazacyclohenicosino[5,4-b][1,4]benzoxazin-10-yl carbamate is used as a pharmaceutical compound for its potential medicinal properties. The presence of various functional groups and the bromine atom in its structure suggests that it may have therapeutic applications, possibly as a drug candidate or an intermediate in the synthesis of other bioactive molecules.
Used in Research and Development:
In the field of chemical research and development, (2E)-22-bromo-14-hydroxy-9,15-dimethoxy-5,11,13,17-tetramethyl-4,26-dioxo-4,9,10,13,14,15,16,17,18,25-decahydro-2,19-methanoazacyclohenicosino[5,4-b][1,4]benzoxazin-10-yl carbamate serves as a subject of study for understanding its chemical properties, reactivity, and potential interactions with biological systems. This knowledge can be crucial for developing new drugs or optimizing existing ones.

Check Digit Verification of cas no

The CAS Registry Mumber 64202-83-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,2,0 and 2 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 64202-83:
(7*6)+(6*4)+(5*2)+(4*0)+(3*2)+(2*8)+(1*3)=101
101 % 10 = 1
So 64202-83-1 is a valid CAS Registry Number.

64202-83-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 7'-Brom-geldanoxazinon

1.2 Other means of identification

Product number -
Other names 7'-Bromodemethoxygelanoxazone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:64202-83-1 SDS

64202-83-1Downstream Products

64202-83-1Relevant articles and documents

GELDANAMYCIN AND DERIVATIVES INHIBIT CANCER INVASION AND IDENTIFY NOVEL TARGETS

-

Page/Page column 40; 41, (2008/06/13)

Geldanamycin derivatives that block the uPA-plasmin network and inhibit growth and invasion by glioblastoma cells and other tumors at femtomolar concentrations are potentially highly active anti-cancer drugs. GA and various 17-amino-17-demethoxygelddanamycin derivatives are disclosed that block HGF/SF-mediated Met tyrosine kinase receptor-dependent uPA activation at fM levels. Other ansamycins (macbecins I and II), GA derivatives, and radicicol required concentrations several logs higher (≥nM) to achieve such inhibition. The inhibitory activity of tested compounds was discordant with the known ability of drugs of this class to bind to hsp90, indicating the existence of a novel target(s) for HGF/SF -mediated events in tumor development. Methods of using such compounds to inhibit cancer cell activities and to treat tumors are disclosed. Such treatment with low doses of these highly active compounds provide an option for treating various Met-expressing tumors, in particular invasive brain cancers, either alone or in combination with conventional surgery, chemotherapy, or radiotherapy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 64202-83-1